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Thrombolysis Is Associated With Consistent Functional
Improvement Across Baseline Stroke Severity
A Comparison of Outcomes in Patients From the Virtual International
Stroke Trials Archive (VISTA)
Nishant K. Mishra, MBBS; Patrick Lyden, MD; James C. Grotta, MD; Kennedy R. Lees, MD, FRCP;
for the VISTA Collaborators
Background and Purpose—Baseline stroke severity predicts outcomes among thrombolysed patients. The baseline
National Institutes of Health Stroke Scale (NIHSS) thresholds are sometimes used to select patients for thrombolysis,
clinical trial enrollment, or both. Using data lodged with Virtual International Stroke Trials Archive, we compared
adjusted outcomes between thrombolysed and nonthrombolysed patients enrolled in neuroprotection trials (1998–2007)
to assess the influence of various levels of baseline NIHSS.
Method—We assessed the association of treatment with outcome, measured across the modified Rankin scale score
distribution, in patients categorized by baseline NIHSS in increments of 4. We used an age and baseline NIHSS adjusted
Cochran-Mantel-Haenszel test followed by proportional odds logistic regression analysis. We report the Cochran-
Mantel-Haenszel P values and estimated odds ratios (OR) for improved modified Rankin scale score distribution with
treatment for patients within each baseline NIHSS category.
Results—Data were available for 5817 patients (1585 thrombolysed and 4232 nonthrombolysed). Baseline severity was
greater among thrombolysed than nonthrombolysed (median baseline NIHSS, 14 vs 13; P0.05). An association of
treatment with outcome was seen independently and was of similar magnitude within each of the baseline NIHSS
categories 5 to 8 (P0.04; OR, 1.25; 95% confidence interval [CI], 1.0–1.6; N278/934 thrombolysed/nonthrombo-
lysed), 9 to 12 (P0.01; OR, 1.3; 95% CI, 1.1–1.6; N404/942), 13 to 16 (P0.05; OR, 1.6; 95% CI, 1.3–2.1;
N342/814), 17 to 20 (P0.05; OR, 1.7; 95% CI, 1.3–2.1; N311/736), and 21 to 24 (P0.05; OR, 1.6; 95% CI,
1.1–2.1; N178/466). No association was observed within baseline NIHSS categories 1 to 4 (P0.8; OR, 1.1; 95% CI,
0.3–4.4; N8/161) or 25 (P0.08; OR, 1.1; 95% CI, 0.7–1.9; N64/179).
Conclusions—In this nonrandomized comparison, outcomes after thrombolysis were significantly better than in untreated
comparators across baseline NIHSS 5 to 24. The significant association was lost only at extremes of baseline NIHSS
when sample sizes were small and confidence limits were wide. (Stroke. 2010;41:2612-2617.)
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Intravenous thrombolysis with alteplase is a proven therapyfor acute ischemic stroke patients presenting before 4.5
hours of symptom onset.1 However, some patients are denied
therapy for fear of poor outcomes.2 European guidelines
recommend that patients with baseline stroke severity, Na-
tional Institutes of Health Stroke Scale (NIHSS) 25, and
minor/rapidly improving strokes should not be thrombol-
ysed,2,3 because it is believed that many patients who show
rapid improvement/have minor strokes would not display
residual deficit, and treatment with thrombolytic therapy
would expose them to risk of complications, such as cerebral
hemorrhage. Similarly, those patients who present with base-
line NIHSS 25 are also supposed to have poorer outcomes
because of excess symptomatic hemorrhages.2–3 Baseline
stroke severity (baseline NIHSS) is known to affect outcomes
among thrombolysed patients4 and therefore was incorpo-
rated for patient selection in the ECASS III trial.1 Although
the regulatory authorities have recommended withholding
thrombolytic therapy among patients with minor/rapidly im-
proving strokes and for those with severe stroke at baseline,
poorer response to therapy in these subgroups has never been
demonstrated in randomized, controlled trials.5 Post hoc
analyses of the NINDS and ECASS-III trials suggest equal
efficacy across severity range, although power to examine
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subgroups is inevitably lower than chosen for the primary
analyses, and patients at extremes of severity were under-rep-
resented.6–8 The logistical challenges involved in generating
randomized trial evidence for these limited subgroups mili-
tate against any prospect for producing a definitive answer in
the foreseeable future. Therefore, we must turn to alternative
sources of evidence.
The Virtual International Stroke Trials Archive (VISTA) is
a repository of data from many rigorously controlled clinical
trials.9 Although most of these trials examined putative
neuroprotectant agents, use of recombinant tissue plasmino-
gen activator was generally recorded. We planned to use data
from VISTA, hypothesizing that clinical practice over the
past decade would have been sufficiently diverse to allow
analysis of existing rigorously collected clinical data lodged
in VISTA to examine the influence of baseline stroke severity
on outcomes after thrombolytic therapy.
Patients and Methods
Data Source and Patients
We collated the demographics, clinical data, and measures of
functional outcome from neuroprotection trials conducted in the
period 1998 to 2007, held within VISTA (www.vista.gla.ac.uk).10
All trials held necessary review board and regulatory approvals, and
patients consented to participation; only anonymous data are held by
VISTA. We sought VISTA data derived from trials in which the
investigational neuroprotection agent was not vasoactive and did not
interfered with clotting or from placebo groups. We excluded any
patient who had cerebral hemorrhage or stroke of undetermined
etiology. To avoid dual publication, we excluded patients who may
have been enrolled in SITS-MOST; we determined this from their
country and date of enrollment. Finally, we excluded patients lacking
our chosen outcome measure, 90-day modified Rankin scale (mRS)
score, or secondary outcome, 90-day NIHSS score. Patients who
died within 90 days were attributed the mRS score of 6 and
categorized separately for NIHSS analysis.
Statistical Analysis
We compared outcome between patients who received thrombolysis
and patients who did not receive thrombolysis (controls) among the
categories of baseline NIHSS scores (4, 5–8, 9–12, 13–16, 17–20,
21–24, and 25). Note that the reason for withholding thrombolysis
in each case was not recorded but will include absence of marketing
approval in the region at that time, clinical uncertainty over the use
of thrombolysis for stroke generally, absence of treatment facilities
for thrombolysis in the hospital at that time, and contraindications to
thrombolysis for the individual patient. For each contrast, we
compared the overall distribution of all 7 categories of day 90 mRS
scores of the 2 groups, ie, from 0 (asymptomatic) through 5
(bed-bound and completely dependent) to 6 (dead). The European
Medicines Evaluation Agency Points to Consider for reporting trials
allow for use of the full distribution of the mRS but suggest that this
may be supported by a secondary analysis of a second outcome
measure, such as NIHSS.11 For analysis of our supporting end point,
NIHSS, we grouped adjacent scores into categories: 0 (no measur-
able deficit), 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, and
25 (most severe neurological deficit) or dead. The distribution of
patients across these categories was then compared between the
groups as it was for mRS.
To test for a significant association of outcome distribution with
thrombolysis exposure, we used the Cochran-Mantel-Haenszel sta-
tistic, adjusting for both age and baseline NIHSS as continuous
variables.12,13 This nonparametric approach avoids invoking an
assumption of proportional odds in which there should be a common
odds ratio across all cut points on the ordinal outcome scale, and we
consider that the Cochran-Mantel-Haenszel test provides the most
conservative estimate of statistical significance. However, it does not
express the extent of the association. For this, we applied logistic
regression analysis, also adjusted for age and baseline NIHSS, to
estimate the odds ratio under the assumption of proportional odds
and its associated 95% confidence interval.
Our choice of baseline factors for adjustment was based on 2
influences. First, age and baseline severity are the 2 most powerful
prognostic factors for stroke and are usually included in outcome
distribution analyses.13–17 Second, age and NIHSS data were available
for our entire sample, whereas other factors of potential interest were
incomplete. However, we also undertook a sensitivity analysis in which
we adjusted for ECASS III variables diabetes and previous stroke. In
addition, we also undertook an adjusted analysis by combining the
variables that differed significantly at baseline; however, if this resulted
in excessive diminution of our sample, we reported the limitations.
Our objective was mainly to undertake ordinal distribution or
“shift” analysis, which is an efficient end point analytic technique
recommended by European Medicines Evaluation Agency.11,18–20
Shift analysis is considered better than dichotomization of end point
measures, although there are differences of opinion.21,22 Dichotomi-
zation is criticized for the statistical information it discards, ie, loss
of power, and shift analysis is especially useful when the treatment
effect is mild and/or uniform across all Rankin categories. Odds
ratios in our analysis express the common odds of an improved
distribution of outcome in association with alteplase treatment.
Cochran-Mantel-Haenszel and logistic regression analyses were
undertaken using SAS 9.2 software (SAS Software Limited, United
Kingdom) and other analyses by Stats Direct software (StatsDirect
Limited, United Kingdom).
Reliable information on symptomatic hemorrhage was not available
because post-treatment imaging was not routinely applied in neuropro-
tection trials to patients who had not been treated with alteplase.
Results
Patient Sample
We collated data on 9665 patients, of whom 5342 (59%) were
enrolled from non-European sites. To avoid dual publication
with SITS-MOST, we excluded 2789 patients (28%) enrolled
from European sites between 2002 and 2006, and 177 patients
for whom we lacked information on country. Complete data
were available for analysis of mRS for 5817 patients and data
on NIHSS were available for 5715 (Figure 1).
All stroke patients were treated as per institutional practice
and stroke guidelines acceptable at the point of trial conduct.
Monitoring for protocol compliance was undertaken on be-
half of sponsors for these trials. This implies that when
thrombolysis was administered, this was in accordance with
marketing authorization for the relevant country, ie, that
treatment commenced within 3 hours of stroke onset; how-
ever, the onset to treatment delay is not recorded for
thrombolysis in these trials. Our data derived mainly from
North American (60%), European (16%), and Australasian
(13%) centers. Baseline characteristics are shown in the
Table. Of the 5817 patients with mRS outcome data, 1585
(27.2%) received thrombolysis.
Does Baseline Stroke Severity Influence
Stroke Outcomes?
In an ordinal logistic regression analysis, we found that
baseline severity (P0.0001), use of recombinant tissue
plasminogen activator, and age were significant predictors of
outcomes. Then, in an age-adjusted ordinal logistic regression
analysis, we found that baseline stroke severity (P0.0001)
and the interaction between severity and use of alteplase
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(P0.04) were associated with outcome of stroke, but we did
not see an independent effect of alteplase (P0.65).
Supported by this interaction test, we classified the base-
line stroke severity into 7 baseline NIHSS score categories: 1
to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, 21 to 24, and 25,
and undertook tests of association for thrombolysis with
outcomes in each of these categories.
Are There Improved Outcomes Across All
Baseline Stroke Severity Categories?
Findings from age and baseline NIHSS-adjusted analysis of
functional outcomes are shown in Figure 2. This essentially
shows a significant association of better outcomes with use of
alteplase for patients presenting with baseline NIHSS 5 to 24.
The patients with NIHSS 4 at baseline had a mixed
distribution of outcomes at 90 days, some Rankin categories
appeared to have improved, and others worsened. Patients
with baseline NIHSS 24 showed generally improved
Rankin distribution with alteplase; however, proportionality
of the treatment effect was maintained.
Findings were consistent for the neurological outcomes (by
NIHSS on day 90) and also for the sensitivity analyses (ie,
unadjusted analysis and analysis adjusting for age, baseline
NIHSS, diabetes, and previous stroke). We could not adjust
for onset to treatment time because time to initiation of
thrombolytic therapy was not recorded within our source
neuroprotection trials. Fifty-nine percent of records lacked
coding for the variable “antithrombotic” (N3432), 4.8%
lacked coding for atrial fibrillation (N278), and 3.2%
lacked coding for patients with previous strokes (N186).
This limitation to our sample precluded a reliable analysis
that was adjusted for all variables that differed at baseline
(age, baseline NIHSS, previous use of antithrombotic drugs,
previous stroke, and atrial fibrillation).
Figure 1. Flow diagram describing selection of data from Virtual International Stroke Trials Archive neuroprotection trials (1998–2007)
for the analyses reported.
Table. Baseline Characteristics of the Patients
Thrombolysis Nonthrombolysed Controls P
Age, median (range) 71 (21–98) N1585 72 (21–101) N4232 0.05
Male 880/1585 55.52% 2226/4232 52.6% 0.05
Baseline NIHSS, median (range) 14 (2–32) N1585 13 (2–37) N4232 0.05
Previous antiplatelet use 429/1078 39.8% 446/1306 34.2% 0.05
Previous anticoagulation use 67/1078 6.2% 198/1306 15.2% 0.05
Previous stroke 319/1555 20.5% 1579/4076 38.7% 0.05
Congestive heart failure 151/1262 12% 164/1409 11.6% 0.79
Diabetes mellitus 342/1548 22.1% 992/3991 24.9% 0.03
Hypertension 1030/1548 66.5% 2827/3991 70.8% 0.05
Atrial fibrillation 398/1548 25.7% 1274/3991 31.3% 0.05
Myocardial infarction 278/1548 18% 691/3991 17.3% 0.57
NIHSS, National Institutes of Health Stroke Scale.
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Discussion
Patients with mild and severe strokes are under-represented in
randomized trials and post-marketing analyses. As a result,
the European Medicines Evaluation Agency marketing au-
thorization for alteplase in acute ischemic stroke lists minor
neurological deficit or symptoms rapidly improving before
start of infusion and severe stroke as assessed clinically (eg,
NIHSS 25) and/or by appropriate imaging techniques as
contraindications.2,23 Such patients do present to hospital
services, however, and this places the physician in a dilemma
of whether to offer treatment. Some experienced physicians
treat such patients. For example, 12% of patients in the
SITS-ISTR thrombolysis registry had a baseline NIHSS score
in the range of 0 to 4, and 4% had severe stroke with NIHSS
25. Many more patients were probably denied treatment. A
Canadian series found that 31% of cases were considered too
mild or improving too rapidly for treatment,19 and a report
from the United States indicates that only 1 in 5 patients with
NIHSS scores8 are treated.6 This cannot be justified on the
basis of observed outcomes. In retrospect, 32% of patients
with cases considered too mild to be treated had either died or
were disabled 90 days later.19 Others7,20–21 report similar
findings. Randomized trials to establish the existence or
extent of benefit at extremes of baseline severity may be
difficult to conduct and delayed in execution. Other sources
of evidence must be examined, and high-quality registry data
are the obvious choice.
In our present nonrandomized comparison of data held in
VISTA, outcomes after thrombolysis were significantly better
than in untreated comparators across baseline NIHSS scores
5 to 24. This significant association was lost only at extremes
of baseline NIHSS (ie, 1–4 and 25). Although the point
estimates for both adjusted and unadjusted odds ratios remain
favorable in the extreme groups, they are lower than those
observed at other levels of stroke severity.
In these extreme groups, the small sample size seriously
undermines the power of the statistical tests and, with wide
confidence intervals, the true point estimate is not reliably
indicated. There is a second statistical issue to consider
relating to the outcome measure that we used. By examining
the full distribution of the mRS, we have used a test that is
less dependent on case-mix than dichotomization. We are
able to use the same test for patients with mild stroke as is
used severe stroke and may still detect benefit. Even so, at the
extremes of baseline severity, outcomes are generally so good
or so poor that only a few mRS categories are well-represented
in the control groups. Both the Cochran-Mantel-Haenszel test
and the proportional odds estimations will be compromised if
some categories are not contributing to the analysis. Effec-
tively, the test of treatment effect will be diluted by the
noncontributing groups. For Cochran-Mantel-Haenszel, this
means that it becomes more difficult to reach statistical
significance; however, but for the proportional odds tests, the
basic assumption has been breached and the effect is not
proportional. There is no easy solution to this problem. If
case-mix is altered to deliver a significant result, then patients
with mild or severe stroke must be excluded, which is the
solution used by the trials. Conversely, if the outcome
measure is varied according to the sample case-mix (the
sliding dichotomy approach discussed by Murray et al24),
then interpretation is rendered difficult. Is an odds ratio for
achieving mRS 0 vs 1 to 6 equivalent to an odds ratio for
achieving mRS 0 to 5 vs 6, ie, is survival free from symptoms
equivalent to survival at any cost?
Here, we have chosen to present 1 analytic approach for all
severities of stroke, but we also illustrate the range of
outcomes at extremes of severity. From these, although the
summary statistics show only a nonsignificant but favorable
trend, we can draw further conclusions. Among patients with
severe stroke, there are evident trends toward benefit across
almost all boundaries of mRS. Among patients with mild
stroke, all boundaries except 0 to 1 vs 2 to 6 show benefit, but
4 of the mRS categories are entirely unrepresented. Our data
show no reason to withhold treatment from either group of
patients but are not in themselves sufficient evidence to
justify treatment.
Our findings draw validity from the fact that our source
clinical trials rigorously reported concomitant treatments and
outcomes and had strict on-site data verification procedures.
However, the nonrandom allocation to treatment vs control
groups is a significant weakness of our design. We could not
determine the degree and cause of exclusion of patients from
Figure 2. Age and baseline severity-
adjusted analyses showing functional out-
comes corresponding to various baseline
NIHSS categories categories. Odds ratios
are derived from proportional odds logis-
tic regression analyses and refer to pro-
portional (common) odds for shift toward
better modified Rankin scale categories
for patients who receive alteplase.
Cochran-Mantel-Haenszel (CMH) test is a
nonparametric test, and it measures the
strength of association between alteplase
use and better outcomes.
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our database. We can only consider factors known to be
associated with prognosis.
We have adjusted statistically for factors that have a large
influence on outcome. We can also ‘anchor’ our findings by
comparison of treatment associations for patients with mod-
erate stroke severity in our study against known treatment
effects in comparable patients from randomized trials. For
example, we find an odds ratio for favorable outcome of 1.3
to 1.6 for patients with baseline NIHSS 9 to 12 and 13 to 16;
the comparable estimate from treatment within 3 hours of
stroke onset in a randomized control trial would be 1.64 and
for 3 to 4.5 hours would be 1.34.25 Our estimates are
comparable and perhaps conservative.
The decay of benefit across later onset to treatment times
raises a second issue. We do not have information on the
onset to treatment delay for alteplase in our current analysis.
Because the patients were permitted only 1 investigational
drug in the participating VISTA trials, with alteplase being
used as standard of care, and because these trials were closely
monitored by their sponsors, we assume that patients were
largely treated within 3 hours of stroke onset. We also assume
that the onset-to-treatment time is comparable to those from
the CASES and SITS-MOST registries (155 [130–175]
minutes and 140 [115–165] minutes, respectively; n6483).
Unfortunately, the latency between stroke onset and record-
ing of initial severity differed between our treatment group
(3.7 hours) and controls (5.1 hours). Severity is associated
with onset to hospital arrival time: patients with more severe
stroke present earlier.26 We adjusted our analyses for stroke
severity, but it is conceivable that residual bias persists. Such
a bias would cause underestimation of true initial severity
among our controls and through the baseline adjustment
would lead us to overestimate treatment effect. It will
influence all patients across our severity range but may be
less evident at extremes of severity: the NIHSS criterion will
be responsible for discouraging use of alteplase, and so the
proportion of patients who are treated with alteplase will have
extremes of NIHSS.
With these caveats, it would be desirable to replicate our
findings. Supporting evidence could come from a comparison
of SITS-ISTR data against VISTA controls, a collaborative
analysis that is underway. We lack data on symptomatic
hemorrhages because patients who are not treated with
thrombolysis generally do not undergo follow-up cerebral
imaging for routine detection of hemorrhagic transformation.
However, the outcome measure that we use takes into account
effects of hemorrhage or other adverse events on function.
We adjusted for age and baseline severity because these are
the established most important variables known to influence
outcomes.27 We could not adjust for all age, baseline NIHSS,
previous use of antithrombotic drugs, previous stroke, and
atrial fibrillation data together because 1 of the contributing
trial programs did not record pretreatment medications. How-
ever, we were able to undertake an adjusted analysis for the
variables that were found significant in ECASS III, namely
diabetes and previous stroke, and our estimates remained
consistent.
Some of the patients in our study received an investiga-
tional medicinal product. Each contributing trial has already
tested for, and excluded, a significant interaction of that
product with alteplase, both in vitro and in vivo.
Conclusion
In conclusion, our findings imply that patients with extremes
of NIHSS scores recorded at baseline may still benefit from
treatment but the supporting evidence remains weak.
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